Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

CRVM is outside Roche and Genentech's historical core focus, which has predominately been in oncology with major drugs like Avastin and Herceptin and, more recently, in rare disease and the ...

Order Your Report Now For A Swift Delivery: Who Are the Leading Companies in the Kadcyla Market? F. Hoffmann-La Roche Ltd. stands out as a major industry participant, significantly influencing ...